Repligen (NASDAQ:RGEN) Releases Quarterly Earnings Results, Beats Expectations By $0.05 EPS

Repligen (NASDAQ:RGEN) announced its earnings results on Tuesday. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05, FiscalAI reports. The business had revenue of $197.91 million for the quarter, compared to analyst estimates of $192.23 million. Repligen had a net margin of 0.25% and a return on equity of 4.66%.

Repligen Price Performance

Repligen stock opened at $135.40 on Tuesday. The business has a 50 day simple moving average of $156.30 and a 200 day simple moving average of $146.71. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.36 and a quick ratio of 7.14. The company has a market capitalization of $7.62 billion, a PE ratio of 6,773.39, a price-to-earnings-growth ratio of 2.48 and a beta of 1.13. Repligen has a one year low of $102.96 and a one year high of $175.77.

Insider Transactions at Repligen

In other Repligen news, Director Karen A. Dawes sold 275 shares of the stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $161.00, for a total transaction of $44,275.00. Following the completion of the transaction, the director directly owned 91,821 shares in the company, valued at $14,783,181. This represents a 0.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Repligen

Several large investors have recently made changes to their positions in the company. UMB Bank n.a. increased its position in shares of Repligen by 13.8% during the 4th quarter. UMB Bank n.a. now owns 758 shares of the biotechnology company’s stock worth $124,000 after purchasing an additional 92 shares in the last quarter. CANADA LIFE ASSURANCE Co grew its stake in Repligen by 0.3% during the third quarter. CANADA LIFE ASSURANCE Co now owns 36,599 shares of the biotechnology company’s stock worth $4,542,000 after buying an additional 100 shares during the last quarter. Itau Unibanco Holding S.A. increased its holdings in shares of Repligen by 38.0% during the fourth quarter. Itau Unibanco Holding S.A. now owns 378 shares of the biotechnology company’s stock worth $62,000 after buying an additional 104 shares in the last quarter. Cerity Partners LLC raised its stake in shares of Repligen by 6.1% in the fourth quarter. Cerity Partners LLC now owns 2,718 shares of the biotechnology company’s stock valued at $445,000 after acquiring an additional 157 shares during the last quarter. Finally, Smartleaf Asset Management LLC boosted its holdings in shares of Repligen by 15.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,327 shares of the biotechnology company’s stock worth $221,000 after acquiring an additional 175 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Canaccord Genuity Group raised their price target on shares of Repligen from $150.00 to $165.00 and gave the stock a “hold” rating in a research report on Wednesday, October 29th. Wall Street Zen raised Repligen from a “hold” rating to a “buy” rating in a research report on Saturday, February 7th. UBS Group upped their price target on Repligen from $190.00 to $200.00 and gave the company a “buy” rating in a report on Friday, January 16th. Wells Fargo & Company lifted their price objective on Repligen from $175.00 to $190.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. Finally, Weiss Ratings upgraded Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, February 17th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $177.92.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.